Pancreatic Cancer - Pipeline Review, H2 2015

Date: December 31, 2015
Pages: 1769
Price:
US$ 2,500.00 US$ 2,125.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: PE633B95348EN
Leaflet:

Download PDF Leaflet

Pancreatic Cancer - Pipeline Review, H2 2015

SUMMARY

Global Markets Direct’s, ‘Pancreatic Cancer - Pipeline Review, H2 2015’, provides an overview of the Pancreatic Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pancreatic Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pancreatic Cancer and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Pancreatic Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Pancreatic Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Pancreatic Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Pancreatic Cancer pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
REASONS TO BUY
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Pancreatic Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Pancreatic Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Pancreatic Cancer Overview
Therapeutics Development
Pancreatic Cancer - Therapeutics under Development by Companies
Pancreatic Cancer - Therapeutics under Investigation by Universities/Institutes
Pancreatic Cancer - Pipeline Products Glance
Pancreatic Cancer - Products under Development by Companies
Pancreatic Cancer - Products under Investigation by Universities/Institutes
Pancreatic Cancer - Companies Involved in Therapeutics Development
Pancreatic Cancer - Therapeutics Assessment
Drug Profiles
Pancreatic Cancer - Recent Pipeline Updates 1241
Pancreatic Cancer - Dormant Projects 1675
Pancreatic Cancer - Discontinued Products 1700
Pancreatic Cancer - Product Development Milestones 1706
Appendix 1714

LIST OF TABLES

Number of Products under Development for Pancreatic Cancer, H2 2015
Number of Products under Development for Pancreatic Cancer - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd..1)
Number of Products under Development by Companies, H2 2015 (Contd..2)
Number of Products under Development by Companies, H2 2015 (Contd..3)
Number of Products under Development by Companies, H2 2015 (Contd..4)
Number of Products under Development by Companies, H2 2015 (Contd..5)
Number of Products under Development by Companies, H2 2015 (Contd..6)
Number of Products under Development by Companies, H2 2015 (Contd..7)
Number of Products under Development by Companies, H2 2015 (Contd..8)
Number of Products under Development by Companies, H2 2015 (Contd..9)
Number of Products under Development by Companies, H2 2015 (Contd..10)
Number of Products under Development by Companies, H2 2015 (Contd..11)
Number of Products under Development by Companies, H2 2015 (Contd..12)
Number of Products under Development by Companies, H2 2015 (Contd..13)
Number of Products under Development by Companies, H2 2015 (Contd..14)
Number of Products under Development by Companies, H2 2015 (Contd..15)
Number of Products under Development by Companies, H2 2015 (Contd..16)
Number of Products under Development by Companies, H2 2015 (Contd..17)
Number of Products under Development by Companies, H2 2015 (Contd..18)
Number of Products under Development by Companies, H2 2015 (Contd..19)
Number of Products under Development by Companies, H2 2015 (Contd..20)
Number of Products under Development by Companies, H2 2015 (Contd..21)
Number of Products under Development by Companies, H2 2015 (Contd..22)
Number of Products under Investigation by Universities/Institutes, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..2)
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Development by Companies, H2 2015 (Contd..4)
Products under Development by Companies, H2 2015 (Contd..5)
Products under Development by Companies, H2 2015 (Contd..6)
Products under Development by Companies, H2 2015 (Contd..7)
Products under Development by Companies, H2 2015 (Contd..8)
Products under Development by Companies, H2 2015 (Contd..9)
Products under Development by Companies, H2 2015 (Contd..10)
Products under Development by Companies, H2 2015 (Contd..11)
Products under Development by Companies, H2 2015 (Contd..12)
Products under Development by Companies, H2 2015 (Contd..13)
Products under Development by Companies, H2 2015 (Contd..14)
Products under Development by Companies, H2 2015 (Contd..15)
Products under Development by Companies, H2 2015 (Contd..16)
Products under Development by Companies, H2 2015 (Contd..17)
Products under Development by Companies, H2 2015 (Contd..18)
Products under Development by Companies, H2 2015 (Contd..19)
Products under Development by Companies, H2 2015 (Contd..20)
Products under Development by Companies, H2 2015 (Contd..21)
Products under Development by Companies, H2 2015 (Contd..22)
Products under Development by Companies, H2 2015 (Contd..23)
Products under Development by Companies, H2 2015 (Contd..24)
Products under Development by Companies, H2 2015 (Contd..25)
Products under Development by Companies, H2 2015 (Contd..26)
Products under Development by Companies, H2 2015 (Contd..27)
Products under Development by Companies, H2 2015 (Contd..28)
Products under Development by Companies, H2 2015 (Contd..29)
Products under Development by Companies, H2 2015 (Contd..30)
Products under Investigation by Universities/Institutes, H2 2015
Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2015 (Contd..2)
Products under Investigation by Universities/Institutes, H2 2015 (Contd..3)
Pancreatic Cancer - Pipeline by 3-V Biosciences, Inc., H2 2015
Pancreatic Cancer - Pipeline by 3B Pharmaceuticals GmbH, H2 2015
Pancreatic Cancer - Pipeline by 4SC AG, H2 2015
Pancreatic Cancer - Pipeline by AB Science SA, H2 2015
Pancreatic Cancer - Pipeline by AbbVie Inc., H2 2015
Pancreatic Cancer - Pipeline by AbGenomics International, Inc., H2 2015
Pancreatic Cancer - Pipeline by Ability Pharma, SL, H2 2015
Pancreatic Cancer - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2015
Pancreatic Cancer - Pipeline by ACF Pharmaceuticals, LLC, H2 2015
Pancreatic Cancer - Pipeline by Adamed Sp. z o.o., H2 2015
Pancreatic Cancer - Pipeline by Adamis Pharmaceuticals Corporation, H2 2015
Pancreatic Cancer - Pipeline by Aduro BioTech, Inc., H2 2015
Pancreatic Cancer - Pipeline by Advantagene, Inc., H2 2015
Pancreatic Cancer - Pipeline by Advaxis, Inc., H2 2015
Pancreatic Cancer - Pipeline by Agenus, Inc., H2 2015
Pancreatic Cancer - Pipeline by AGV Discovery, SAS, H2 2015
Pancreatic Cancer - Pipeline by AIMM Therapeutics B.V., H2 2015
Pancreatic Cancer - Pipeline by Alchemia Limited, H2 2015
Pancreatic Cancer - Pipeline by Alethia Biotherapeutics Inc., H2 2015
Pancreatic Cancer - Pipeline by Allinky Biopharma, H2 2015
Pancreatic Cancer - Pipeline by Almac Discovery Limited, H2 2015
Pancreatic Cancer - Pipeline by Altor BioScience Corporation, H2 2015
Pancreatic Cancer - Pipeline by Ambrx, Inc., H2 2015
Pancreatic Cancer - Pipeline by Amgen Inc., H2 2015
Pancreatic Cancer - Pipeline by Anavex Life Sciences Corp., H2 2015
Pancreatic Cancer - Pipeline by Andarix Pharmaceuticals, Inc., H2 2015
Pancreatic Cancer - Pipeline by ANP Technologies, Inc., H2 2015
Pancreatic Cancer - Pipeline by APEIRON Biologics AG, H2 2015
Pancreatic Cancer - Pipeline by Apexigen, Inc., H2 2015
Pancreatic Cancer - Pipeline by Aphios Corporation, H2 2015
Pancreatic Cancer - Pipeline by APIM Therapeutics AS, H2 2015
Pancreatic Cancer - Pipeline by Apogenix GmbH, H2 2015
Pancreatic Cancer - Pipeline by Aposense Ltd., H2 2015
Pancreatic Cancer - Pipeline by Arch Biopartners, Inc., H2 2015
Pancreatic Cancer - Pipeline by Argon Pharma S.L., H2 2015
Pancreatic Cancer - Pipeline by ArQule, Inc., H2 2015
Pancreatic Cancer - Pipeline by Array BioPharma Inc., H2 2015
Pancreatic Cancer - Pipeline by Ascenta Therapeutics, Inc., H2 2015
Pancreatic Cancer - Pipeline by Astellas Pharma Inc., H2 2015
Pancreatic Cancer - Pipeline by AstraZeneca Plc, H2 2015
Pancreatic Cancer - Pipeline by ATLAB Pharma SAS, H2 2015
Pancreatic Cancer - Pipeline by Aurigene Discovery Technologies Limited, H2 2015
Pancreatic Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H2 2015
Pancreatic Cancer - Pipeline by Axcentua Pharmaceuticals AB, H2 2015
Pancreatic Cancer - Pipeline by Azaya Therapeutics, Inc., H2 2015
Pancreatic Cancer - Pipeline by Basilea Pharmaceutica AG, H2 2015
Pancreatic Cancer - Pipeline by Bavarian Nordic A/S, H2 2015
Pancreatic Cancer - Pipeline by Bayer AG, H2 2015
Pancreatic Cancer - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2015
Pancreatic Cancer - Pipeline by BerGenBio AS, H2 2015
Pancreatic Cancer - Pipeline by Beta Pharma, Inc., H2 2015
Pancreatic Cancer - Pipeline by Bexion Pharmaceuticals, LLC., H2 2015
Pancreatic Cancer - Pipeline by Biomar Microbial Technologies, H2 2015
Pancreatic Cancer - Pipeline by Biomunex Pharmaceuticals, H2 2015
Pancreatic Cancer - Pipeline by Bioncotech Therapeutics S.L., H2 2015
Pancreatic Cancer - Pipeline by Bionomics Limited, H2 2015
Pancreatic Cancer - Pipeline by BiOrion Technologies B.V., H2 2015
Pancreatic Cancer - Pipeline by Biotest AG, H2 2015
Pancreatic Cancer - Pipeline by Biothera, Inc., H2 2015
Pancreatic Cancer - Pipeline by Biouniversa s.r.l., H2 2015
Pancreatic Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2015
Pancreatic Cancer - Pipeline by Boston Biomedical, Inc., H2 2015
Pancreatic Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2015
Pancreatic Cancer - Pipeline by Calithera Biosciences, Inc., H2 2015
Pancreatic Cancer - Pipeline by Cantex Pharmaceuticals, Inc., H2 2015
Pancreatic Cancer - Pipeline by Cavion LLC, H2 2015
Pancreatic Cancer - Pipeline by Celgene Corporation, H2 2015
Pancreatic Cancer - Pipeline by Cellectar Biosciences, Inc., H2 2015
Pancreatic Cancer - Pipeline by Cellectis S.A., H2 2015
Pancreatic Cancer - Pipeline by Celsion Corporation, H2 2015
Pancreatic Cancer - Pipeline by Centrose LLC, H2 2015
Pancreatic Cancer - Pipeline by Ceronco Biosciences, H2 2015
Pancreatic Cancer - Pipeline by ChemoCentryx, Inc., H2 2015
Pancreatic Cancer - Pipeline by Chiome Bioscience, Inc., H2 2015
Pancreatic Cancer - Pipeline by Clovis Oncology, Inc., H2 2015
Pancreatic Cancer - Pipeline by Coare Biotechnology, Inc., H2 2015
Pancreatic Cancer - Pipeline by Concordia Healthcare Corp., H2 2015
Pancreatic Cancer - Pipeline by Confluence Life Sciences, Inc., H2 2015
Pancreatic Cancer - Pipeline by Cornerstone Pharmaceuticals, Inc., H2 2015
Pancreatic Cancer - Pipeline by Critical Outcome Technologies Inc., H2 2015
Pancreatic Cancer - Pipeline by CritiTech, Inc., H2 2015
Pancreatic Cancer - Pipeline by CrystalGenomics, Inc., H2 2015
Pancreatic Cancer - Pipeline by CTI BioPharma Corp., H2 2015
Pancreatic Cancer - Pipeline by CureFAKtor Pharmaceuticals, LLC, H2 2015
Pancreatic Cancer - Pipeline by Cyclacel Pharmaceuticals, Inc., H2 2015
Pancreatic Cancer - Pipeline by CytomX Therapeutics, Inc., H2 2015
Pancreatic Cancer - Pipeline by CytoVac A/S, H2 2015
Pancreatic Cancer - Pipeline by CytRx Corporation, H2 2015
Pancreatic Cancer - Pipeline by CyTuVax B.V., H2 2015
Pancreatic Cancer - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2015
Pancreatic Cancer - Pipeline by DEKK-TEC, Inc., H2 2015
Pancreatic Cancer - Pipeline by Dicerna Pharmaceuticals, Inc., H2 2015
Pancreatic Cancer - Pipeline by e-Therapeutics Plc, H2 2015
Pancreatic Cancer - Pipeline by Eisai Co., Ltd., H2 2015
Pancreatic Cancer - Pipeline by Eleison Pharmaceuticals LLC, H2 2015
Pancreatic Cancer - Pipeline by Eli Lilly and Company, H2 2015
Pancreatic Cancer - Pipeline by Endor Nanotechnologies SL, H2 2015
Pancreatic Cancer - Pipeline by Ensol Biosciences Inc., H2 2015
Pancreatic Cancer - Pipeline by Erytech Pharma SA, H2 2015
Pancreatic Cancer - Pipeline by Esperance Pharmaceuticals, Inc., H2 2015
Pancreatic Cancer - Pipeline by Etubics Corporation, H2 2015
Pancreatic Cancer - Pipeline by Exelixis, Inc., H2 2015
Pancreatic Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
Pancreatic Cancer - Pipeline by FibroGen, Inc., H2 2015
Pancreatic Cancer - Pipeline by Five Prime Therapeutics, Inc., H2 2015
Pancreatic Cancer - Pipeline by Fountain Biopharma Inc., H2 2015
Pancreatic Cancer - Pipeline by Fujifilm Corporation, H2 2015
Pancreatic Cancer - Pipeline by Fusion Antibodies Limited, H2 2015
Pancreatic Cancer - Pipeline by Ganymed Pharmaceuticals AG, H2 2015
Pancreatic Cancer - Pipeline by Genelux Corporation, H2 2015
Pancreatic Cancer - Pipeline by Genentech, Inc., H2 2015
Pancreatic Cancer - Pipeline by Genmab A/S, H2 2015
Pancreatic Cancer - Pipeline by Gilead Sciences, Inc., H2 2015
Pancreatic Cancer - Pipeline by GlaxoSmithKline Plc, H2 2015
Pancreatic Cancer - Pipeline by Globeimmune, Inc., H2 2015
Pancreatic Cancer - Pipeline by GlycoMimetics, Inc., H2 2015
Pancreatic Cancer - Pipeline by Golden Biotechnology Corp., H2 2015
Pancreatic Cancer - Pipeline by Halozyme Therapeutics, Inc., H2 2015
Pancreatic Cancer - Pipeline by HanAll Biopharma Co., Ltd., H2 2015
Pancreatic Cancer - Pipeline by Heat Biologics, Inc., H2 2015
Pancreatic Cancer - Pipeline by HEC Pharm Co., Ltd., H2 2015
Pancreatic Cancer - Pipeline by Helix BioPharma Corp., H2 2015
Pancreatic Cancer - Pipeline by Huabo Biopharm Co., Ltd., H2 2015
Pancreatic Cancer - Pipeline by iCeutica, Inc., H2 2015
Pancreatic Cancer - Pipeline by Ignyta, Inc., H2 2015
Pancreatic Cancer - Pipeline by Immodulon Therapeutics Ltd., H2 2015
Pancreatic Cancer - Pipeline by Immune Pharmaceuticals Inc., H2 2015
Pancreatic Cancer - Pipeline by Immunomedics, Inc., H2 2015
Pancreatic Cancer - Pipeline by Immunotope, Inc., H2 2015
Pancreatic Cancer - Pipeline by Immunovo BV, H2 2015
Pancreatic Cancer - Pipeline by Incuron, LLC, H2 2015
Pancreatic Cancer - Pipeline by Incyte Corporation, H2 2015
Pancreatic Cancer - Pipeline by Inflection Biosciences Limited, H2 2015
Pancreatic Cancer - Pipeline by Innopharmax Inc., H2 2015
Pancreatic Cancer - Pipeline by Inovio Pharmaceuticals, Inc., H2 2015
Pancreatic Cancer - Pipeline by Intica Biomedical, Inc., H2 2015
Pancreatic Cancer - Pipeline by Inventiva SAS, H2 2015
Pancreatic Cancer - Pipeline by Io Therapeutics, Inc., H2 2015
Pancreatic Cancer - Pipeline by Ipsen S.A., H2 2015
Pancreatic Cancer - Pipeline by Isarna Therapeutics GmbH, H2 2015
Pancreatic Cancer - Pipeline by Jasco Pharmaceuticals, LLC., H2 2015
Pancreatic Cancer - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2015
Pancreatic Cancer - Pipeline by Kadmon Corporation, LLC, H2 2015
Pancreatic Cancer - Pipeline by KAEL-GemVax Co., Ltd., H2 2015
Pancreatic Cancer - Pipeline by Kalos Therapeutics, Inc., H2 2015
Pancreatic Cancer - Pipeline by Kancera AB, H2 2015
Pancreatic Cancer - Pipeline by Karyopharm Therapeutics, Inc., H2 2015

LIST OF FIGURES

Number of Products under Development for Pancreatic Cancer, H2 2015
Number of Products under Development for Pancreatic Cancer - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

COMPANIES MENTIONED

3-V Biosciences, Inc.
3B Pharmaceuticals GmbH
4SC AG
AB Science SA
AbbVie Inc.
AbGenomics International, Inc.
Ability Pharma, SL
Acetylon Pharmaceuticals, Inc.
ACF Pharmaceuticals, LLC
Adamed Sp. z o.o.
Adamis Pharmaceuticals Corporation
Aduro BioTech, Inc.
Advantagene, Inc.
Advaxis, Inc.
Agenus, Inc.
AGV Discovery, SAS
AIMM Therapeutics B.V.
Alchemia Limited
Alethia Biotherapeutics Inc.
Allinky Biopharma
Almac Discovery Limited
Altor BioScience Corporation
Ambrx, Inc.
Amgen Inc.
Anavex Life Sciences Corp.
Andarix Pharmaceuticals, Inc.
ANP Technologies, Inc.
APEIRON Biologics AG
Apexigen, Inc.
Aphios Corporation
APIM Therapeutics AS
Apogenix GmbH
Aposense Ltd.
Arch Biopartners, Inc.
Argon Pharma S.L.
ArQule, Inc.
Array BioPharma Inc.
Ascenta Therapeutics, Inc.
Astellas Pharma Inc.
AstraZeneca Plc
ATLAB Pharma SAS
Aurigene Discovery Technologies Limited
AVEO Pharmaceuticals, Inc.
Axcentua Pharmaceuticals AB
Azaya Therapeutics, Inc.
Basilea Pharmaceutica AG
Bavarian Nordic A/S
Bayer AG
Bellicum Pharmaceuticals, Inc.
BerGenBio AS
Beta Pharma, Inc.
Bexion Pharmaceuticals, LLC.
Biomar Microbial Technologies
Biomunex Pharmaceuticals
Bioncotech Therapeutics S.L.
Bionomics Limited
BiOrion Technologies B.V.
Biotest AG
Biothera, Inc.
Biouniversa s.r.l.
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
Bristol-Myers Squibb Company
Calithera Biosciences, Inc.
Cantex Pharmaceuticals, Inc.
Cavion LLC
Celgene Corporation
Cellectar Biosciences, Inc.
Cellectis S.A.
Celsion Corporation
Centrose LLC
Ceronco Biosciences
ChemoCentryx, Inc.
Chiome Bioscience, Inc.
Clovis Oncology, Inc.
Coare Biotechnology, Inc.
Concordia Healthcare Corp.
Confluence Life Sciences, Inc.
Cornerstone Pharmaceuticals, Inc.
Critical Outcome Technologies Inc.
CritiTech, Inc.
CrystalGenomics, Inc.
CTI BioPharma Corp.
CureFAKtor Pharmaceuticals, LLC
Cyclacel Pharmaceuticals, Inc.
CytomX Therapeutics, Inc.
CytoVac A/S
CytRx Corporation
CyTuVax B.V.
Daewoong Pharmaceutical Co., Ltd.
DEKK-TEC, Inc.
Dicerna Pharmaceuticals, Inc.
e-Therapeutics Plc
Eisai Co., Ltd.
Eleison Pharmaceuticals LLC
Eli Lilly and Company
Endor Nanotechnologies SL
Ensol Biosciences Inc.
Erytech Pharma SA
Esperance Pharmaceuticals, Inc.
Etubics Corporation
Exelixis, Inc.
F. Hoffmann-La Roche Ltd.
FibroGen, Inc.
Five Prime Therapeutics, Inc.
Fountain Biopharma Inc.
Fujifilm Corporation
Fusion Antibodies Limited
Ganymed Pharmaceuticals AG
Genelux Corporation
Genentech, Inc.
Genmab A/S
Gilead Sciences, Inc.
GlaxoSmithKline Plc
Globeimmune, Inc.
GlycoMimetics, Inc.
Golden Biotechnology Corp.
Halozyme Therapeutics, Inc.
HanAll Biopharma Co., Ltd.
Heat Biologics, Inc.
HEC Pharm Co., Ltd.
Helix BioPharma Corp.
Huabo Biopharm Co., Ltd.
iCeutica, Inc.
Ignyta, Inc.
Immodulon Therapeutics Ltd.
Immune Pharmaceuticals Inc.
Immunomedics, Inc.
Immunotope, Inc.
Immunovo BV
Incuron, LLC
Incyte Corporation
Inflection Biosciences Limited
Innopharmax Inc.
Inovio Pharmaceuticals, Inc.
Intica Biomedical, Inc.
Inventiva SAS
Io Therapeutics, Inc.
Ipsen S.A.
Isarna Therapeutics GmbH
Jasco Pharmaceuticals, LLC.
Jiangsu Hengrui Medicine Co., Ltd.
Kadmon Corporation, LLC
KAEL-GemVax Co., Ltd.
Kalos Therapeutics, Inc.
Kancera AB
Karyopharm Therapeutics, Inc.
Keystone Nano, Inc.
Komipharm International Co., Ltd.
Kura Oncology, Inc.
LivTech, Inc.
Lymphocyte Activation Technologies, S.A.
MabVax Therapeutics Holdings, Inc.
MacroGenics, Inc.
Meabco A/S
Mebiopharm Co., Ltd.
MediaPharma s.r.l.
Medicenna Therapeutics, Inc
MedImmune, LLC
Medivation, Inc.
Merck & Co., Inc.
Merck KGaA
Merrimack Pharmaceuticals, Inc.
Merus B.V.
Monopar Therapeutics LLC
Morphotek, Inc.
MSM Protein Technologies, Inc.
Multimmune GmbH
NanoCarrier Co., Ltd.
Nanotherapeutics, Inc.
NantKwest, Inc.
Natco Pharma Limited
NatureWise Biotech & Medicals Corporation
NeoPharm Co., Ltd.
Nerviano Medical Sciences S.r.l.
NewLink Genetics Corporation
NormOxys, Inc.
Northwest Biotherapeutics, Inc.
Novartis AG
NuCana BioMed Limited
Omeros Corporation
Omnitura Therapeutics Inc.
Oncodesign SA
Oncodrone BV
Oncology Research International Limited
Oncolytics Biotech Inc.
Oncomatryx Biopharma, S.L.
OncoMed Pharmaceuticals, Inc.
Oncothyreon Inc.
Oncovir, Inc.
Ono Pharmaceutical Co., Ltd.
Optimum Therapeutics, LLC
Oryx GmbH & Co. KG
Oscotec Inc.
Otsuka Holdings Co., Ltd.
Pfizer Inc.
Pharma Mar, S.A.
Pharma Two B Ltd
PharmAbcine, Inc.
Pharmacyclics, Inc.
PharmaCyte Biotech, Inc.
Pharmedartis GmbH
Phoenix Biotechnology, Inc.
Pique Therapeutics
Plexxikon Inc.
Polaris Pharmaceuticals, Inc.
Precision Biologics, Inc.
Prescient Therapeutics Limited
Prima BioMed Ltd.
ProMetic Life Sciences Inc.
Qu Biologics Inc.
Quest PharmaTech Inc.
Quimatryx, S.L.
Raptor Pharmaceutical Corp.
RedHill Biopharma Ltd.
Redx Pharma Plc
Rexahn Pharmaceuticals, Inc.
Rigontec GmbH
Samyang Holdings Corporation
Sanofi
Sareum Holdings Plc
SATT Nord
Savoy Pharmaceuticals, Inc.
SignPath Pharma Inc
Silence Therapeutics Plc
Sillajen Biotherapeutics
Sorrento Therapeutics, Inc.
Strongbridge Biopharma plc
Sumitomo Dainippon Pharma Co., Ltd.
Sunesis Pharmaceuticals, Inc.
Symphogen A/S
Synovo GmbH
Synta Pharmaceuticals Corp.
Taiho Pharmaceutical Co., Ltd.
Taiwan Liposome Company, Ltd.
Takara Bio Inc.
Takeda Pharmaceutical Company Limited
Tara Immuno-Oncology Therapeutics LLC
Targovax AS
TetraLogic Pharmaceuticals
Teva Pharmaceutical Industries Limited
TG Therapeutics, Inc.
Tokai Pharmaceuticals, Inc.
Tolero Pharmaceuticals, Inc.
Transgene SA
TVAX Biomedical, Inc.
Tyg Oncology Ltd.
Tyrogenex, Inc.
ValiRx Plc
VasGene Therapeutics, Inc.
Vaxeal Holding SA
Vaximm AG
Vaxon Biotech
VCN Biosciences SL
Vect-Horus S.A.S.
Verlyx Pharma Inc.
Vertex Pharmaceuticals Incorporated
Vicus Therapeutics, LLC
Virobay Inc.
Welichem Biotech Inc.
Wilex AG
XOMA Corporation
XTuit Pharmaceuticals, Inc.
Zeria Pharmaceutical Co., Ltd.
Zhejiang BetaPharma Co., Ltd.
Zymeworks Inc.
Skip to top


Ask Your Question

Pancreatic Cancer - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: